quinazolines has been researched along with Barrett Esophagus in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertele', V; Garattini, S; Gerardi, C; Joppi, R | 1 |
| Canto, M; Ding, P; Dunbar, KB; Eshleman, JR; Feldmann, G; Goff, D; Haffner, MC; Heckrodt, TJ; Hector, A; Holland, SJ; Hong, SM; Karikari, C; Maitra, A; Marimuthu, A; Meeker, AK; Montgomery, EA; Nelkin, BD; Pandey, A; Riggins, GJ; Roa, JC; Singh, R; Wang, JS; Yu, J; Zhang, J | 1 |
| Bhatt, A; Davison, JM; Foxwell, T; Gibson, MK; Hoppo, T; Hough, B; Jobe, BA; Komatsu, Y; Kosovec, JE; Malhotra, U; Rotoloni, CL; Sanz, AF; Zaidi, AH | 1 |
| Pühringer-Oppermann, FA; Sarbia, M; Stein, HJ | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
2 review(s) available for quinazolines and Barrett Esophagus
| Article | Year |
|---|---|
Letting post-marketing bridge the evidence gap: the case of orphan drugs.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Barrett Esophagus; Cladribine; Dihematoporphyrin Ether; Ductus Arteriosus, Patent; Hepatolenticular Degeneration; Humans; Ibuprofen; Leukemia, Hairy Cell; Mitotane; Orphan Drug Production; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Quinazolines; Thrombocythemia, Essential; Zinc Acetate | 2016 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
3 other study(ies) available for quinazolines and Barrett Esophagus
| Article | Year |
|---|---|
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Axl Receptor Tyrosine Kinase; Barrett Esophagus; Benzocycloheptenes; Cell Movement; Esophageal Neoplasms; Female; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lapatinib; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; ral GTP-Binding Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Survival Rate; Triazoles | 2010 |
Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease.
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Benzamides; Caspase 3; Disease Models, Animal; Esophageal Neoplasms; Gastroesophageal Reflux; Gene Expression; Hedgehog Proteins; Immunoenzyme Techniques; Ki-67 Antigen; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, G-Protein-Coupled; RNA, Messenger; Smoothened Receptor | 2013 |
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Barrett Esophagus; Chromatography, High Pressure Liquid; Codon; ErbB Receptors; Esophageal Neoplasms; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2007 |